Boston Therapeutics Inc (BTHE): Clinical Study Reveals Chewable Type 2 Diabetes Drug PAZ320

Ken Tassey, president of Boston Therapeutics, Inc. (OTCQB: BTHE), discusses enrolling patients in a Phase IIb clinical study on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes. A total of 24 patients with Type 2 diabetes currently being treated with metformin will be administered PAZ320 under double-blind, placebo-controlled conditions, according to Boston Therapeutics.“This trial is designed to build upon the positive results from our Dartmouth Medical Center Phase IIa trial for PAZ320, recently published in the peer-reviewed journal, Endocrine Practice,” said David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics in a press release. “In the Phase IIa study, PAZ320 was well tolerated in patients taking various anti-diabetic agents, including metformin. The Phase IIb trial, which focuses on patients taking only metformin, is the next step in the investigation of this compound as a potential adjunct to metformin in patients living with Type 2 diabetes. We believe it is important to better control glucose levels throughout the day, given the many complications that stem from uncontrolled diabetes.”The company said PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose.